Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6852W HIGH $6.10
Volume
2.76 K
Value Traded
3.11 K
Short % Float
0.08%
+6.48%Week
+0.56%1 Month
+442%3 Month
+622.67%6 Month
-87.28%5 Year
-65.03%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
81.32 M
EPS (TTM)
0.70
P/E Ratio
7.74
Ent. Value
90.10 M
Total Shares
15.00 M
Float Shares
7.21 M
Insiders
39.17%
Institutions
2.99%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INCR Catalyst Timeline
Dated clinical, regulatory and corporate events for Intercure Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Intercure Ltd.
108Total events
0Upcoming
33Tier-1 (high impact)
2021 to 2026Coverage
Event history 50
▲Other Regulator MilestoneEx-US Regulatory
Final settlement with Israeli Tax Authorities and Compensation Fund for indirect damages
▼Equity OfferingCorporate
Private placement financing of NIS 22 million (up to NIS 54 million) led by pharma-focused hedge funds
◆Pipeline PrioritizationCorporate
Strategic review of U.S. medical cannabis opportunities initiated
medical cannabissource ↗
●Quarterly UpdateCorporate
Plans to file Annual Report on Form 20-F for year ended December 31, 2025
◆Other Regulator MilestoneEx-US Regulatory
Expected closing of ISHI acquisition subject to regulatory approvals
▲Quarterly UpdateCorporate
First meaningful revenues from German medical cannabis market reported
▲Partnership / LicenseCorporate
InterCure signs Share Purchase Agreement and Collaboration Agreement with Cannasoul
▲Partnership / LicenseCorporate
Strategic investment and collaboration with Cannasoul R&D Ltd.
▲Quarterly UpdateCorporate
First half 2025 financial results with NIS 130 million revenue and positive operating cash flow
▲Product LaunchCANNDOCPost-Market
CANNDOC resumed launching over 20 SKUs including first Nir Oz products
▲Quarterly UpdateCorporate
Expected Q1 2025 revenue over NIS 70 million, sequential growth over 25%
●Management ChangeCorporate
Ehud Barak steps down as Chairman, succeeded by Alexander Rabinovich
▼Equity OfferingCorporate
Completed private placement financing securing NIS 66 million (~$18.2 million)
▲Manufacturing MilestoneCMC / Inspection
Resumed production at Nir Oz facility and delivered first batches since October 7, 2023
▼Equity OfferingCorporate
Private placement of ordinary shares and warrants to raise NIS 66M (up to NIS 107M)
◆Debt Royalty FinancingCorporate
Binding loan commitment of NIS 30M from a leading Israeli bank
▲Partnership / LicenseCookiesCorporate
Expansion of strategic partnership with Cookies to Germany
●Quarterly UpdateCorporate
First half 2024 financial results: revenue NIS 126M, adjusted EBITDA NIS 21M
▲IP Litigation RulingIP / Competition
Class action lawsuit dismissed by Tel Aviv-Yafo District Court
▲Quarterly UpdateCorporate
Announced FY2023 revenue of NIS 356 million and adjusted EBITDA of NIS 61 million
◆Quarterly UpdateCorporate
Preliminary results for 2H 2023 and full year 2023 to be filed by early March 2024
▲Product LaunchPost-Market
Commercial launches of GMP products in UK and Germany (continued)
medical cannabissource ↗
◆Quarterly UpdateCorporate
Annual General Meeting of Shareholders to be held on December 14, 2023
▲IP Litigation RulingIP / Competition
Arbitrator decides in favor of InterCure in Cannolam dispute
Past FDA Catalysts and PDUFA Decisions
How INCR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Intercure Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every INCR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rush Gregory SOfficer (Chief Financial Officer) | Option | -71,005 | $0.00 | 09/01/2017 |
Hedge Fund 13F Activity
Hedge Funds invested in INCR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in INCR for Q2 2026. | ||||
INCR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INCR ranks across every disease it competes in
Competitive Position is a premium feature
See how INCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINCR News
INCRInterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
InterCure Ltd. has confirmed that it has regained compliance with Nasdaq's minimum bid price requirement after previously receiving a delisting notice. The company met the requirement by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This compliance ensures that InterCure remains listed on the Nasdaq Global Market.
Read more →INCR▲ +28.7%on this news
InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
InterCure Ltd. has finalized a NIS 230 million settlement for indirect damages from the October 2023 attacks. This settlement will assist in the rehabilitation of its Nir Oz facility, which was severely damaged. The company aims to restore full production and expand into the German medical cannabis market, reflecting a positive outlook despite previous challenges.
Read more →INCRInterCure Ltd. Announces 1-for-5 Reverse Share Split
InterCure Ltd. has announced a 1-for-5 reverse share split to comply with Nasdaq's minimum bid price requirement. The split, approved by shareholders, will adjust the number of outstanding shares and is set to take effect on August 24, 2026. The company aims to maintain its Nasdaq listing while appealing any potential delisting determination.
Read more →INCR▲ +17.4%on this news
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
InterCure Ltd. has announced a binding term sheet for a private placement financing of NIS 22 million, which may increase to NIS 54 million. The funding, led by institutional investors including the CEO, aims to support the company's growth strategy and expansion in regulated cannabis markets, particularly in Germany. The placement is subject to certain conditions, including shareholder approval.
Read more →INCR▲ +9.3%on this news
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
InterCure Ltd. has completed the first tranche of its acquisition of Botanico, enhancing its portfolio with exclusive U.S. cannabis genetics and advanced technologies. Following the recent federal rescheduling of medical cannabis, the company is evaluating opportunities in regulated U.S. markets. InterCure also reports increasing demand in Germany, with plans for new product launches.
Read more →INCR▲ +5.5%on this news
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NI
InterCure Ltd. announced its financial results for 2025, reporting revenues of over NIS 270 million and a positive operating cash flow of NIS 17 million. The company noted a net loss of NIS 37 million and continued efforts to recover from the impacts of the October 7, 2023 attacks. As part of its recovery, InterCure resumed production and launched numerous new medical cannabis products during the year. Additionally, significant strategic partnerships and global market expansion were highlighted, particularly in Germany, marking a positive outlook going forward.
Read more →INCRInterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement NEW YORK and
InterCure Ltd. received a notification from Nasdaq indicating its ordinary shares do not meet the minimum bid price requirement of $1.00 per share. The company has a 180-day compliance period to regain compliance, with options for an additional period if necessary. InterCure plans to monitor its share price closely and is considering a reverse share split to address the issue. Despite the challenge, the company's shares will continue to trade on the Nasdaq Global Market during this timeframe.
Read more →INCR▼ -5.8%on this news
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash 1 of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Ad
InterCure Ltd. reported preliminary estimated revenue of NIS 265 million for 2025, indicating an 11% increase from 2024. The company also achieved its twelfth consecutive half-year of positive Adjusted EBITDA, reflecting overall growth and operational success. Notably, the second half of 2025 saw a nearly 20% revenue increase compared to the same period in the previous year, driven partly by the company's entry into the German market. InterCure plans to further expand its operations in Germany and other markets as part of its global growth strategy.
Read more →INCRNOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 30, 2025 To the shareholders of InterCure Ltd.: Notice is hereby given that an Annual General Meeting (the " Meeting ") of the shareholders of Inter
InterCure Ltd. has announced its Annual General Meeting of shareholders, scheduled for December 30, 2025, at its legal office in Tel Aviv, Israel. Shareholders of record as of December 2, 2025, will be eligible to attend and vote at this meeting. The agenda for the meeting has not been disclosed, and shareholders are encouraged to participate, either in person or via proxy. Proxies must be submitted by December 29, 2025, to ensure representation at the meeting.
Read more →INCRInterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation Agreements formalize research partnership combining InterCure's global pharmaceutic
InterCure Ltd. has signed strategic investment and collaboration agreements with Cannasoul R&D Ltd., formalizing a partnership to develop cannabis therapeutics. This includes a 28% ownership stake in Cannasoul with an exclusive option to increase to 51%. The timing aligns with reports of the U.S. administration considering cannabis rescheduling, which may unlock new opportunities. The partnership will leverage Cannasoul's research capabilities and appoint Prof. Dedi Meiri to enhance scientific oversight.
Read more →INCRInterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating
InterCure Ltd. announced its financial results for the first half of 2025, reporting revenues of NIS 130 million and a positive operating cash flow of NIS 12 million. This performance reflects the company's ability to maintain profitability through challenging environments, with a continuous record of positive Adjusted EBITDA for eleven halves. The company is also pursuing an acquisition of ISHI and is watching regulatory changes in the U.S. cannabis market, which they believe will provide growth opportunities. However, ongoing conflicts pose potential risks to their operations in Israel.
Read more →INCRInterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strateg
InterCure Ltd. has announced its strategic acquisition of ISHI (Botanico Ltd.), enhancing its access to premium U.S. cannabis technology and brands. This acquisition marks a significant milestone in InterCure's expansion strategy, coinciding with favorable regulatory momentum in the U.S. cannabis market. InterCure will gain partnerships with top-tier cannabis operators and access to innovative cultivation technologies, which are expected to enhance operational capabilities and market competitiveness. The transaction will close in Q1 2026, pending regulatory approvals.
Read more →INCRInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 2024 results were affected by damages to our southern facility caused
InterCure has announced its financial results for FY2024, reporting revenues of NIS 239 million and an Adjusted EBITDA of NIS 24 million. Despite the adverse effects from damages caused by the October 7 terrorist attack and the ongoing war in Gaza, the company achieved profitability for the eighteenth and nineteenth consecutive quarters. InterCure has also secured funding for facility recovery and plans to expand its strategic partnership with Cookies in Europe. The company is optimistic about a strong start to Q1 2025, expecting continued growth.
Read more →INCRInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025
InterCure announced its FY2024 results, reporting revenues of NIS 239 million and an Adjusted EBITDA of NIS 24 million. The results were affected by damages from the October 7 terrorist attack and the ongoing war in Gaza. Despite these challenges, the company expects a strong start to 2025 with over 25% sequential growth and has expanded its partnership with Cookies™ into Germany. The company remains focused on recovery and international expansion.
Read more →INCRInterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak NEW YORK &
InterCure Ltd. announced the appointment of Alexander Rabinovich as the new Chairman of the Board, succeeding Ehud Barak who is stepping down. Rabinovich, who has been the CEO for the past five years, has overseen significant growth and strategic partnerships for the company. InterCure recently completed financing to support the recovery of its Nir Oz facility, which has been impacted by ongoing conflicts. The company is focused on restoring operations and expanding its product portfolio.
Read more →INCRInterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
InterCure Ltd. announced that Alexander Rabinovich will replace Ehud Barak as Chairman of the Board, effective February 13, 2025. Barak, who has served for six years, is stepping down to pursue personal endeavors. The company has secured approximately $18.2 million in financing to support the recovery of its Nir Oz facility, which was impacted by recent conflicts. Rabinovich emphasizes the company's commitment to patient care and international expansion.
Read more →INCRNOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025 To the shareholders of Intercure Ltd.: Notice is hereby given that an Extraordinary General Meeting (the " Meeting ") of the sharehol
Intercure Ltd. has announced an upcoming Extraordinary General Meeting for shareholders scheduled on January 27, 2025. The meeting will take place at the offices of the Company's attorneys in Bnei Brak, Israel. Shareholders as of December 27, 2024, will be able to attend and vote on various matters, with specific procedures outlined for proxy voting. The company's board has recommended shareholders vote "FOR" the proposed items.
Read more →INCR▲ +11.2%on this news· ran to +34% by day 1
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-wa
InterCure has successfully secured NIS 66 million in funding to aid the recovery of its Nir Oz Facility, which could increase to NIS 107 million. Key shareholders including the CEO are participating in the funding, which also includes a loan from a major Israeli bank. This funding is expected to facilitate a return to profitability and support the company's expansion into international markets such as Germany, the UK, and Australia. The company anticipates additional compensation from Israeli authorities for war-related damages, further aiding its recovery efforts.
Read more →INCR▲ +11.2%on this news· ran to +34% by day 1
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025 To the shareholders of InterCure Ltd.: Notice is hereby given that an Extraordinary General Meeting (the " Meeting ") of the sharehol
InterCure Ltd. has announced an Extraordinary General Meeting of its shareholders scheduled for January 27, 2025, at the offices of Doron Tikotzky Kantor Gutman & Amit Gross in Bnei Brak, Israel. Shareholders as of December 27, 2024, will be entitled to notice of and vote at the meeting. The Company’s Board of Directors recommends that shareholders vote in favor of the proposed items on the agenda. The notice details the procedures for voting, including proxy submissions for those unable to attend in person.
Read more →INCR▲ +5.2%on this news
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 30, 2024 To the shareholders of Intercure Ltd.: Notice is hereby given that an Annual General Meeting (the " Meeting ") of the shareholders of Inter
Intercure Ltd. has announced its Annual General Meeting scheduled for December 30, 2024, taking place at the offices of its attorneys in Bnei Brak, Israel. Shareholders must be on record by December 2, 2024, to gain access to vote on various agenda items. Proxy voting details are provided for those unable to attend in person, enhancing shareholder participation. The Board of Directors recommends voting in favor of all proposed items at the meeting.
Read more →About Intercure Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next INCR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime